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Human breast cancer is a typical hormone-dependent tumour, and
various endocrine treatments have been employed in advanced or
recurrent cases. These treatments have also been performed as a
part of post-operative adjuvant therapy. The measurement of
oestrogen receptor a (ER-a) in cancer tissues is now an important
procedure in order to discriminate between hormone-dependent
and -independent tumours. Although about 60% of patients with
ER-a in their cancer tissues responded to endocrine therapies,
fewer than 10% of patients without ER-a also responded
(McGuire et al, 1991). Furthermore, ER-a-negative tumours are
associated with poorer histological differentiation, higher growth
fraction and a somewhat poorer clinical outcome (McGuire et al,
1991). Hormone resistance could partly result from the loss of the
ER-a protein, or might be due to the presence of mutant/variant
ER-a in breast cancer (McGuire et al, 1991; Katzenellenbogen
et al, 1997). However, no significant alterations such as insertions,
deletions, rearrangements, or point mutations within the ER-a
gene have been reported (Karnik et al, 1994; Roodi et al, 1995).
Thus, genetic alterations of the ER-a gene at the DNA level might
account for only a portion of ER-a expression.
DNA methylation is known to be involved in eukaryotic gene
control, and can effect development and tumorigenesis (Falette et
al, 1990). The ER-a gene was found to be methylated in placental
tissues, but normal breast tissues exhibit a different methylation
pattern, as assessed by HpaII and MspI restriction enzyme-digests
(Falette et al, 1990). In addition, specific sites in the hormone-
binding domain of the ER-a gene were observed to be differently
methylated in different human breast tumour specimens (Falette
et al, 1990). In particular, previous studies correlated the lack of
ER-a gene expression in ER-a-negative breast tumour cells with
hypermethylation of a CpG island in the 5¢ region of the ER-a
gene (Ottaviano et al, 1994; Ferguson et al, 1995). Thus, DNA
methylation may be an additional molecular measure of the
genetic heterogeneity in breast cancer.
ER-a has two specific promoters, distal (P0) and proximal (P1),
which induce almost identical transcripts in size due to different
splicing, and the only difference between the two transcripts is the
most 5¢ untranslated 164 and 120 bases, which are unique for each
transcript (Grandien et al, 1995). Hayashi et al (1997) reported that
the enhancement of the ER-a mRNA expression from the distal
promoter played an essential role in the mechanisms of over-
expressing ER-a protein in human mammary tumours, implying
that a tumour-specific regulation of ER-a expression involved use
of the distal promoter. However, Grandien et al (1995) reported
that both promoters were active in MCF-7 cancer cells, and that
only the P1 promoter was transcribed in ZR-75-1 breast cancer
cells.
In this paper we examined alterations in DNA methylation at
the distal and proximal promoter regions of the ER-a gene using
polymerase chain reaction (PCR)-based methylation assay and
Southern blot assay in breast cancers. We also discuss the clinical
significance of this epigenetic change.
MATERIALS AND METHODS
Patients and DNA extraction
Tissues from 56 patients with primary breast cancers were
obtained by surgical resection in the Second Department of
Surgery of Nagoya City University Medical School. None of the
patients had a familial history of breast cancer. Of the 56 tumours,
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20 were papillo-tubular carcinomas, eight were solid-tubular
carcinomas, 25 were scirrhous carcinomas and three were invasive
lobular carcinomas. Patient ages at the operation ranged from 33
to 86 years (median 52). Genomic DNA from the breast cancer
specimens was extracted by standard techniques.
Oestrogen and progesterone receptor determinations
Cytosolic ER-a and progesterone receptor (PR) levels were
measured using enzyme immunoassay (ER– and PgR–EIA,
Abbott Laboratories, Chicago, IL, USA). A positive ER-a and PR
status was defined as more than 15 fmol mg–1 protein.
PCR-based methylation assay
We examined the methylation status at P0 and P1 promoter regions
of the ER-a gene (Figure 1). A PCR-based assay was performed as
described previously (Gonzalez-Zuluenta et al, 1995), with some
modification. One microgram of genomic DNA was digested
overnight with 10 units of the methylation-sensitive restriction
enzyme HpaII under conditions specified by the manufacturer
(Takara, Kyoto, Japan). Fifty nanograms of the digested DNA
were amplified by PCR. The primer sequences are 5¢-TCT-
CCCCTCACTCCCCACTGC-3¢, 5¢-GAAATCAAAACAAGCC-
TACCC-3¢ for the P0 promoter region, 5¢-AGCAG-
CAAGCCCGCCGTGTACAAC-3¢ (368–391) and 5¢-CTCGCG-
CACCGTGTAGCCGCTGGG-3¢ (638–661) for the P1 promoter
region. Conditions were as follows: 95°C for 5 min, 25 cycles of
94°C for 1 min, annealing temperature (60°C for P0 and 58°C for
P1) for 1 min and 70°C for 1 min, followed by incubation at 72°C
for 5 min. PCR conditions were determined by cycle curve and
DNA concentration curve. To rule out the possibility of false posi-
tives due to incomplete digestion and overcycling of the PCR
amplifications, the digestions of each sample and PCR amplifica-
tion were performed at least twice in independent experiments.
Undigested DNA and MspI digested DNA samples were amplified
as positive and negative controls respectively. PCR products were
resolved on 1.5% agarose gels. Loss or reduction of the PCR prod-
ucts following digestion by HpaII was assessed as unmethylation.
Southern hybridization
To confirm the results of PCR-based methylation analysis,
Southern hybridization was performed. Ten micrograms of genetic
DNA were digested with 100 units of NotI overnight, and subse-
quently digested with 100 units of EcoRI. After electrophoresis on
a 1.2% agarose gel, samples were transferred to Hybond N+ nylon
membrane (Amersham Corp., Buckinghampshire, UK). Filters
were hybridized with a pOR3 probe, which was generously
provided by Professor P Chambon, and labelled with [a-32P]dCTP
using a Multiprime-labelling kit (Amersham), as previously
described.
RESULTS
DNA methylation at P0, P1 promoter regions of the
ER-a gene in breast cancers
We investigated 56 breast cancers for methylation at the P0 and P1
promoter regions of the ER-a gene with a PCR-based assay.
Unmethylation at the P0 and P1 promoter regions was observed in
15 (26.8%) and 25 (44.6%) of 56 breast cancers using PCR-based
assay respectively (Figure 2A, B and Table 1). To confirm the
results of the PCR-based methylation assay, we also performed
genomic Southern hybridization. In unmethylated samples, double
digestion with EcoRI and NotI yielded 1.9 kb and 1.2 kb frag-
ments. If samples were methylated, 3.1 kb bands would be
detected. We studied ten samples that showed abnormal methyla-
tion in PCR-based assay. As shown in Figure 2B, four breast
cancers showed methylation of the NotI sites in Southern
hybridization assay, and one breast cancer showed unmethylation.
The agreement between the two methods was nine of ten (90%).
On the other hand, frequency of unmethylation at the P1 promoter
region was higher than that at P0 promoter region. The methyla-
tion at the P1 region correlated with that at the P0 region (Table 2).
Additionally, the tumours with the ER-a gene hypermethylated at
both promoter regions had a definitely negative ER-a protein
value (Figure 3).
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Figure 1 CpG density and restriction sites of the ER gene and its upstream region. The ER-a has two specific promoters, distal (P0) and proximal (P1), that are
almost identical in size due to different splicing. Methylation was examined using PCR-based assay. PCR product (292 bp) at the P0 promoter region included
one CCGG site (open circle, –2085C), and that (294 bp) at the P1 promoter region included two CCGG sites (460C and 478C). NotI site (closed circle, 426C) is near
the CCGG site at the P1 promoter region. Arrows show the primers for PCRs1984 H Iwase et al
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Methylation status and clinicopathologic factors in
breast cancers
Twenty of 29 patients with ER -a protein-positive tumours, and
five of 27 with negative tumours were unmethylated at the P1
promoter region of the ER-a gene. The incidence of methyla-
tion was highly negatively correlated with ER-a  expression
(P= 0.0002). A similarly negative correlation was observed at the
P0 promoter region (P= 0.0154). Methylation at the P0 and P1
regions was also negatively correlated with PR expression.
However, there was no correlation between methylation and any
other clinicopathologic factors (Table 1).
DISCUSSION
Tumours failing to express ER-a would be oestrogen-independent
and would most likely be resistant to anti-oestrogen therapy.
Johnston et al, 1995) reported that the overall frequency of ER-a
expression measured by immunohistochemical assay was reduced
from 51% (37/72) at the initial operation to 29% (21/72) at
progression or relapse. Thus, hormone resistance would partly
result from the loss of the ER-a protein. Roodi et al (1995)
reported that, in the majority of primary breast cancers, the ER -a -
negative phenotype was due to deficient ER-a expression at the
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Figure 2Examples of methylation analysis. (A) Examples of PCR-based
methylation assay at the P1 promoter region of the ER-a gene. U,
undigested; H, digested by HpaII; M, digested by MspI. Cases 1, 3 and 5 are
shown as methylation. Cases 2 and 4 are assessed as unmethylation.
(B) Examples of PCR-based methylation assay at the P0 region of the ER-a
gene. Cases 2, 3 and 5 are assessed as methylation. Cases 1 and 4 are
assessed as unmethylation. (C) Southern blot analysis following digestion by
NotI. U, undigested control. Cases 1, 3, 4, 5 and 6 can be assessed as
unmethylation, and case 2 is assessed as methylation and cases 7 and 8 are
assessed as hetero types with both methylation and unmethylation
Table 1Relationship between DNA methylation at the P0 and P1 promoter regions of the oestrogen receptor gene and clinicopathologic factors
P0 region P1 region
Methylated Unmethylated Methylated Unmethylated
ER + 17 12 9 20
–243 P = 0.0154* 22 5 P = 0.0002**
PR + 16 8 9 15
–257 P = 0.37 22 10 P = 0.030*
Age < 50 17 6 15 8
³50 24 9 P > 0.999 16 17 P = 0.2785
n + 17 7 13 11
–248 P = 0.7677 18 14 P > 0.999
t< 2cm 5 3 5 3
³2cm 36 12 P = 0.6676 26 22 P = 0.7198
HG I 10 6 9 7
II 17 7 P = 0.1757 13 11 P = 0.9861
III 7 0 4 3
Total 41 15 31 25
ER: oestrogen receptor, PR: progesterone receptor, n: axillary lymph node metastasis, t: tumor size, HG: histological grade, P: Fisher’s exact probability test.
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Figure 3 ER-a value and methylation status at the P0 and P1 promoter
regions of the ER gene. The boxes represent the mean and the 70%
confidential interval; bars s.d. Group 1, unmethylation at both promoter
regions, had higher ER-a values than other groups (1 vs 2; P = 0.0057,
1 vs 3; P = 0.0132, 1 vs 4; P < 0.001, statistical analysis by Fisher’s
protected least significant difference)ER methylation in breast cancer 1985
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transcriptional or post-transcriptional level, and was not the result
of mutations in the coding region of the ER-a gene. In our
previous studies, there were neither germline nor somatic muta-
tions in the ER gene in 14 patients with ER-a-negative and PR-
positive breast tumours as assessed by single-strand conformation
polymorphism analysis and DNA sequencing (Iwase et al, 1996).
Furthermore, we did not find a role for the loss of heterozygosity
(LOH) of the ER-a gene in the lack of ER-a function in breast
cancer tissues (Iwase et al, 1995). The mutation of one allele and
the loss or replacement of a chromosomal segment containing the
other allele were not accompanied by changes in ER-a expression.
Thus, genetic alterations in the ER-a gene at the DNA level might
account for only a portion of hormone independence.
The methylation of CpG islands of DNA induces a dilatation of
a major groove and a kink in a minor groove at opposite sides of
the double helix loop (Baylin et al, 1998). These conformation
changes in chromosomes result in changes of interaction between
DNA and core histone particles. There have been many reports on
various genes concerning suppression of the promoter function by
DNA methylation. In addition, DNA methylation of a specific
gene will affect its expression (Baylin et al, 1998). Hyper-
methylation within the promoters of selected genes appears to be
especially common in all types of human haematopoietic
neoplasms, and is usually associated with inactivation of involved
genes such as p15, p16 (Gonzalez-Zulueta et al, 1995) and
E-cadherin (Hennig et al, 1995). The ER-a gene was found to be
methylated in placental tissues, but normal breast tissues exhibited
a different methylation pattern, as assessed by HpaII and MspI
restriction enzyme digests (Falette et al, 1990). In addition,
specific sites in the hormone-binding domain of the ER-a gene
were observed to be differently methylated in different human
breast tumour specimens. Although methylation of the ER-a gene
varied among tumours, the degree of methylation did not correlate
with the levels of receptor-protein expression (Falette et al, 1990;
Watts et al, 1992). However, these studies used a large ER gene
probe (pOR8) that corresponded to internal ER sequences. The
inactivation of ER-a gene expression is associated with de novo
methylation of cluster CpG sites located in and around the
promoter of the gene in ER-a-negative breast tumours (Ottaviano
et al, 1994; Lapidus et al, 1998) and colorectal tumours (Ahuja et
al, 1997). Furthermore, unmethylation of the ER-a gene in ER-a-
negative breast cancer cells treated with two inhibitors of DNA
methylation, 5-azacytidine or 5-aza-2¢-deoxycytidine, can reacti-
vate ER-a gene expression (Ferguson et al, 1997). Lapidus et al
(1998) reported that all samples from normal breast epithelia were
unmethylated at ER-a gene CpG island using bisulphite and PCR
assay. In our investigation all DNA samples extracted from normal
breast tissues were unmethylated (data not shown). Thus, DNA
methylation of the ER-a gene may contribute to ER-a protein
expression.
We used PCR-based methylation-sensitive restriction enzymes
prior to PCR amplification. However, this method has the potential
of generating false positive signals (methylation present) because
of inefficient enzyme digestion or overamplification in the subse-
quent PCR reaction. To avoid such signals, we performed the
digestion of each sample and PCR amplification at least twice in
independent experiments, and we confirmed the methylation
status by conventional Southern hybridization. The results agreed
well with those of PCR-based methylation assay. Furthermore, this
region, located from 400 to 500 bp from ER-a gene start site, is
the most important region of ER CpG island with respect to ER-a
expression (Lapidus et al, 1998). In our data, the frequency of
unmethylation at the P1 promoter region (44.6%) was higher than
that at the P0 promoter region (26.8%). The correlation between
ER-a expression and methylation at the P1 promoter region
(P = 0.0002) was higher than that at the P0 promoter region
(P = 0.0154). This result shows that ER-a expression might be
more influenced by unmethylation at the proximal promoter
region than that at the distal promoter region. Additionally,
tumours with the ER-a gene hypermethylated at both promoter
regions had definitely negative ER-a values. In other words, these
results showed that hypermethylation at the promoter regions of
the ER-a gene might be quite important for ER negativity accom-
panying tumour progression.
Chen et al (1998) reported that the ER-a CpG island in C4:2
cells, a subclone of T47D cells without ER-a expression,
remained unmethylated. This result shows that the loss of ER-a in
these specific breast cancer cells must be due to a mechanism
other than methylation. However, we supposed that methylation at
the distal promoter region of the ER-a gene should be examined in
such cell lines, and that they might be due to a difference between
clinical cases and cell lines. In our data, several cases without
ER-a expression actually had unmethylation at either the P0 or P1
region of the ER gene.
In conclusion, this epigenetic change, ER gene CpG island
methylation, might control ER-a expression, and might play an
important role of loss in the hormone dependence in ER-a-
negative recurrent tumours arising from ER-a-positive tumours.
Therefore, there is a possibility that the methylation status, which
can be detected from genomic DNA of the tumour, may be a good
marker to determine the hormone dependency in breast tumours.
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